Açıklama
Nicholas’s journey from Alaska to Philadelphia for care shows how gene therapy can change lives for children with the once-fatal metachromatic leukodystrophy. Learn more: http://www.chop.edu/leukodystrophy
This is a story of hope, science and determination. When Lizzie and James welcomed their son Nicholas in a remote Alaskan village, they already knew the devastating impact of metachromatic leukodystrophy (MLD) — a rare genetic disease that affects the brain and nervous system. Without treatment, MLD is fatal in childhood. The family had already endured the loss of one child to the disease, and another was facing a swift decline. Thanks to early testing and rapid coordination, their youngest child Nicholas was diagnosed within one week of his birth and referred to Children’s Hospital of Philadelphia (CHOP). CHOP has one of the nation’s leading leukodystrophy centers and is a qualified treatment center for Lenmeldy™, the first FDA-approved gene therapy for pre-symptomatic MLD.
This video follows Nicholas’s extraordinary journey from Alaska to Philadelphia for lifesaving care. Learn how CHOP experts worked across state lines and healthcare systems to deliver a breakthrough treatment before symptoms began — and how their advocacy was instrumental in getting MLD added to the federal newborn screening list, a milestone announced by the FDA in December 2025.
Timestamps:
00:00 – Introduction: Nicholas’s Story
00:00 – What is Metachromatic Leukodystrophy (MLD)?
00:00 – Why Early Diagnosis Matters
00:00 – How Gene Therapy Works to Stop Disease Progression
00:00 – CHOP’s Role in Advancing Newborn Screening and Treatment Access
00:00 – Hope for the Future
About CHOP’s Leukodystrophy Center:
CHOP provides comprehensive care and cutting-edge therapies for children with rare genetic conditions like MLD. Our interdisciplinary team is committed to research, innovation and advocacy to ensure more children have access to lifesaving treatments.
Learn More:
CHOP Leukodystrophy Center
Gene Therapy at CHOP